Ask AI
ProCE Banner Activity

Diagnosis, Prognosis, and Treatment of Essential Thrombocythemia (ET) and Polycythemia Vera (PV): A Concise Resource for Healthcare Professionals

PDF

Download this brief resource with clinical pearls related to the diagnosis, thrombotic risk assessment, and treatment of patients with essential thrombocythemia and polycythemia vera.

Released: January 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme LLC

Target Audience

This activity is intended for hematologists and other healthcare professionals caring for patients with essential thrombocythemia and polycythemia vera.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify and evaluate thrombotic presentations that may be indicative of underlying ET or PV.

  • Apply best practices in ET and PV diagnosis, including appropriate use of bone marrow biopsy and molecular testing for accurate subtype classification.

  • Utilize prognostic scoring systems and immune biomarker data (e.g., Triple A model, MIPSS-ET, MIPSS-PV) to assess thrombotic risk and guide personalized treatment planning.

  • Implement shared decision-making strategies to align treatment goals with patient values, literacy levels, and logistical needs.

  • Prepare to integrate emerging second-line therapies into clinical practice for patients with ET or PV who are intolerant or resistant to front-line therapy.

Faculty Disclosure

Primary Author

Andrew Kuykendall, MD: consultant/advisor/speaker: Bristol Myers Squibb, Geron, GSK, Incyte, Protagonist, Sobi, Takeda; researcher: Janssen, Kartos.